Micrornas in drug-induced liver injury

Journal of Clinical and Translational Hepatology

Volumn 2, Issue 3, 2014, Pages 162-169

  Li, Li Min ^a   Wang, Dong ^a   Zen, Ke ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Biomarker; Diagnosis; Drug induced liver injury (DILI); MicroRNA

Indexed keywords

EID: 84959208029     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2014.00015     Document Type: Review

References (101)

1. Acikgoz A, Giri S, Bader A. Detection of nanolevel drug metabolites in an organotypic culture ofprimary human hepatocytes and porcine hepatocytes with special reference to a two-compartment model. Int J Nanomed 2012; 7:5859–5872.
2. Bjornsson E, Bergmann O, Bjornsson HK, Olafsson S. The frequency of drug-induced liver injury (DILI) among patients receiving potentially hepatotoxic drugs: a population based study. Hepatology 2012;56:594a– 595a. doi: 10.1002/hep.25702.
3. Idilman R, Bektas M, Cinar K, Toruner M, Cerit ET, Doganay B, et al. The Characteristics and Clinical Outcome of Drug-induced Liver Injury A Singlecenter Experience. J Clin Gastroenterol 2010;44:E128–E132. doi: 10.1097/MCG.0b013e3181c5e9cc.
4. Leise MD, Poterucha JJ, Talwalkar JA. Drug-Induced Liver Injury. Mayo Clin Proc 2014;89:95–106. doi: 10.1016/j.mayocp.2013.09.016.
5. Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 2011;89:788–790. doi: 10.1038/clpt.2011.63.
6. Chen MJ, Vijay V, Shi Q, Liu ZC, Fang H, Tong WD. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 2011; 16:697–703. doi: 10.1016/j.drudis.2011.05.007.
7. Reuben A, Koch DG, Lee WM, Grp ALFS. Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study. Hepatology 2010;52: 2065–2076. doi: 10.1002/hep.23937.
8. Shi Q, Hong HX, Senior J, Tong W. Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol 2010;4:225–234. doi: 10.1586/egh.10.8
9. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-induced Liver Injury in the United States. Gastroenterology 2008; 135:1924–1934. doi: 10.1053/j.gastro.2008.09.011.
10. Grant LM, Rockey DC. Drug-induced liver injury. Curr Opin Gastroenterol 2012;28:198–202. doi: 10.1097/MOG.0b013e3283528b5d.
11. Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol 2013;25:825–829. doi: 10.1097/MEG.0b013e32835f6889.
12. Li LM, Chen L, Deng GH, Tan WT, Dan YJ, Wang RQ, et al. SLCO1B1*15 haplotype is associated with rifampin-induced liver injury. Mol Med Rep 2012;6:75–82. doi: 10.3892/mmr.2012.900.
13. Lucena MI, Molokhia M, Shen YF, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. Gastroenterology 2011;141:338– 347. doi: 10.1053/j.gastro.2011.04.001.
14. Watkins PB, Seeff LB. Drug-induced liver injury: Summary of a single topic Clinical research conference. Hepatology 2006;43:618–631. doi: 10.1002/hep.21095.
15. Zopf Y, Rabe C, Neubert A, Gassmann KG, Rascher W, Hahn EG, et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol 2008;64:999–1004. doi: 10.1007/s00228-008-0494-6.
16. Watkins PB. Idiosyncratic liver injury: Challenges and approaches. Toxicol Pathol 2005;33:1–5. doi: 10.1080/01926230590888306.
17. Lindblom P, Rafter I, Copley C, Andersson U, Hedberg JJ, Berg AL, et al. Isoforms of alanine aminotransferases in human tissues and serum Differential tissue expression using novel antibodies. Arch Biochem Biophys 2007;466:66–77. doi: 10.1016/j.abb.2007.07.023.
18. Russmann S, Kullak-Ublick GA, Grattagliano I. Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity. Curr Med Chem 2009;16: 3041–3053. doi: 10.2174/092986709788803097.
19. Pasipanodya JG, Gumbo T. Clinical and Toxicodynamic Evidence that HighDose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently Used. Antimicrob Agents Chemother 2010;54:2847–2854. doi: 10.1128/AAC.01567-09.
20. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16: 3041–3053. doi: 10.2174/092986709788803097.
21. Tarantino G, Di Minno MND, Capone D. Drug-induced liver injury: Is it somehow foreseeable? World J Gastroenterol 2009;15:2817–2833. doi: 10.3748/wjg.15.2817.
22. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis 2007;11:525– 548, vi. doi: 10.1016/j.cld.2007.06.006.
23. van Swelm RPL, Laarakkers CMM, van der Kuur EC, Morava-Kozicz E, Wevers RA, Augustijn KD, et al. Identification of Novel Translational Urinary Biomarkers for Acetaminophen-Induced Acute Liver Injury Using Proteomic Profiling in Mice. Plos One 2012;7:e49524. doi: 10.1371/journal. pone.0049524
24. Ryan PM, Bourdi M, Korrapati MC, Proctor WR, Vasquez RA, Yee SB, et al. Endogenous Interleukin-4 Regulates Glutathione Synthesis Following Acetaminophen-Induced Liver Injury in Mice. Chem Res Toxicol 2012;25: 83–93. doi: 10.1021/tx2003992.
25. Martin-Murphy BV, Holt MP, Ju C. The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol Lett 2010;192:387–394. doi: 10.1016/j.toxlet.2009.11.016.
26. Yin H, Cheng LL, Holt M, Hail N, MacLaren R, Ju C. Lactoferrin Protects Against Acetaminophen-induced Liver Injury in Mice. Hepatology 2010;51: 1007–1016. doi: 10.1002/hep.23476.
27. Ganey PE, Luyendyk JP, Maddox JF, Roth RA. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 2004;150:35–51. doi: 10.1016/j.cbi.2004.09.002.
28. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4:489–499. doi: 10.1038/nrd1750.
29. Uetrecht J. Idiosyncratic drug reactions: Current understanding. Annu Rev Pharmacol 2007;47:513–539. doi: 10.1146/annurev.pharmtox.47. 120505.105150.
30. Cosgrove BD, King BM, Hasan MA, Alexopoulos LG, Farazi PA, Hendriks BS, et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009;237:317–330. doi: 10.1016/j.taap.2009.04.002.
31. Peters TS. Do preclinical testing strategies help predict human hepatotoxic potentials. Toxicol Pathol 2005;33:146–154. doi: 10.1080/019262305905 22121.
32. Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov Today 2003;8:832–837. doi: 10.1016/S1359-6446(03)02816-2.
33. Lucena MI, Andrade RJ, Martinez C, Ulzurrun E, Garcia-Martin E, Borraz Y, et al. Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008; 48:588–596. doi: 10.1002/hep.22370.
34. Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006;44:1581–1588. doi: 10.1002/hep.21424.
35. Uetrecht J. Immunoallergic Drug-Induced Liver Injury in Humans. Semin Liver Dis 2009;29:383–392. doi: 10.1055/s-0029-1240007.
36. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral Medications with Significant Hepatic Metabolism at Higher Risk for Hepatic Adverse Events. Hepatology 2010;51:615–620. doi: 10.1002/hep.23317.
37. Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics 2010;11:607–611. doi: 10.2217/pgs.10.24.
38. Daly AK, Donaldson PT, Bhatnagar P, Shen YF, Pe’er I, Floratos A, et al. HLAB(star)5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816–819. doi: 10.1038/ng.379.
39. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao XJ, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxibrelated liver injury. Nat Genet 2010;42:711–714. doi: 10.1038/ng.632.
40. Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, Andrade RJ. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to druginduced idiosyncratic liver injury (DILI). Brit J Pharmacol 2007;150:808– 815. doi: 10.1038/sj.bjp.0707122.
41. Usui T, Mise M, Hashizume T, Yabuki M, Komuro S. Evaluation of the Potential for Drug-Induced Liver Injury Based on in Vitro Covalent Binding to Human Liver Proteins. Drug Metab Dispos 2009;37:2383–2392. doi: 10.1124/dmd.109.028860.
42. Makarova SI. Human N-acetyltransferases and drug-induced hepatotoxicity. Curr Drug Metab 2008;9:545. doi: 10.2174/138920008784892047.
43. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. ClinLiver Dis 2007;11:477–505, v. doi: 10.1016/j.cld.2007.06.003.
44. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246–59. doi: 10.1053/j.gastro.2010.04.001.
45. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008;14:6774–6785. doi: 10.3748/wjg.14.6774.
46. Pollock NR, Rolland JP, Kumar S, Beattie PD, Jain S, Noubary F, et al. A Paper-Based Multiplexed Transaminase Test for Low-Cost, Point-of-Care Liver Function Testing. Sci Transl Med 2012;4:152ra129. doi: 10.1126/scitranslmed.3003981.
47. Souza LJ, Alves JG, Nogueira RM, Gicovate Neto C, Bastos DA, Siqueira EW, et al. Aminotransferase changes and acute hepatitis in patients with dengue fever: analysis of 1,585 cases. Braz J Infect Dis 2004;8:156–163. doi: 10.1590/S1413-86702004000200006.
48. Kuo CH, Tai DI, Chang-Chien CS, Lan CK, Chiou SS, Liaw YF. Liver biochemical tests and dengue fever. Am JTrop Med Hyg 1992;47:265–270.
49. Xu HM, Chen Y, Xu J, Zhou Q. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. World J Gastroenterol 2012; 18:5972–2978. doi: 10.3748/wjg.v18.i41.5972.
50. David S, Hamilton JP. Drug-induced Liver Injury. US Gastroenterol Hepatol Rev 2010;6:73–80.
51. Tran T, Lee WM. DILI: New Insights into Diagnosis and Management. Curr Hepat Rep 2013;12:53–58. doi: 10.1007/s11901-012-0159-x.
52. Shi Q, Hong H, Senior J, Tong W. Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol 2010;4:225–434. doi: 10.1586/egh.10.8.
53. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005;41:380–382. doi: 10.1002/hep.20548.
54. Shabaneh Al-Tamimi HA, McDonald R. Elevated alanine aminotransferase levels associated with polymyositis: can this be due to muscle injury? J Clin Rheumatol 2008;14:363–364. doi: 10.1097/RHU.0b013e318190b4a6.
55. Zed PJ, Krenzelok EP. Treatment of acetaminophen overdose. Am J Health Syst Pharm 1999;56:1081–1091; quiz 1091-1093.
56. McMillian M, Nie AY, Parker JB, Leone A, Bryant S, Kemmerer M, et al. A gene expression signature for oxidant stress/reactive metabolites in rat liver. Biochem Pharmacol 2004;68:2249–2261. doi: 10.1016/j.bcp.2004.08.003.
57. Hirode M, Omura K, Kiyosawa N, Uehara T, Shimuzu T, Ono A, et al. Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy. J Toxicol Sci 2009;34:281–293. doi: 10.2131/jts.34.281.
58. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008;245:194–205. doi: 10.1016/j.tox.2007.11.021.
59. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–297. doi: 10.1016/S0092-8674(04)00045-5.
60. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843–854. doi: 10.1016/0092-8674(93)90529-Y.
61. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215–233. doi: 10.1016/j.cell.2009.01.002.
62. Ambros V. The functions of animal microRNAs. Nature 2004;431:350–355. doi: 10.1038/nature02871.
63. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003;113:673–676. doi: 10.1016/S00928674(03)00428-8.
64. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Brit J Haematol 2008;141: 672–675. doi: 10.1111/j.1365-2141.2008.07077.x.
65. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, PogosovaAgadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. P Natl Acad Sci U S A 2008;105:10513–10518. doi: 10.1073/pnas.0804549105.
66. Chen X, Ba Y, Ma LJ, Cai X, Yin Y, Wang KH, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997–1006. doi: 10.1038/cr.2008.282.
67. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. Plos One 2008;3: e3148. doi: 10.1371/journal.pone.0003148.
68. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009; 60:167–179. doi: 10.1146/annurev.med.59.053006.104707.
69. Ng E, Chong W, Jin H, Lam E, Shin V, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375–1381. doi: 10.1136/gut.2008.167817.
70. Zen K, Zhang C. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012;32:326–348. doi: 10.1002/med.20215.
71. Tung J. Exploring microRNA biomarkers for disease monitoring and response to therapy. Bioanalysis 2012;4:2204.
72. Fukushima T, Hamada Y, Yamada H, Horii I. Changes of microRNA expression in rat liver treated by acetaminophen or carbon tetrachloride– regulating role of micro-RNA for RNA expression. J Toxicol Sci 2007;32: 401–409. doi: 10.2131/jts.32.401.
73. Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O. Induction of microRNAome deregulation in rat liver by longterm tamoxifen exposure. Mutat Res 2007;619:30–37. doi: 10.1016/j.mrfmmm.2006.12.006.
74. Yoshioka W, Higashiyama W, Tohyama C. Involvement of microRNAs in dioxin-induced liver damage in the mouse. Toxicol Sci 2011;122:457–465. doi: 10.1093/toxsci/kfr130.
75. Endo S, Yano A, Fukami T, Nakajima M, Yokoi T. Involvement of miRNAs in the early phase of halothane-induced liver injury. Toxicology 2014;319:75– 84. doi: 10.1016/j.tox.2014.02.011.
76. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 2006;66:9090– 9098. doi: 10.1158/0008-5472.CAN-06-1403.
77. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol 2009;76:702–709. doi: 10.1124/mol.109.056986.
78. Yokoi T, Nakajima M. Toxicological implications of modulation of gene expression by microRNAs. Toxicol Sci 2011;123:1–14. doi: 10.1093/toxsci/kfr168.
79. Yokoi T, Nakajima M. microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 2013;53:377–400. doi: 10.1146/annurev-pharmtox011112-140250.
80. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009;106:4402–4407. doi: 10.1073/pnas.0813371106.
81. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010;56:1830–1838. doi: 10.1373/clinchem.2010.147850.
82. Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012;56:1946–1957. doi: 10.1002/hep.25873.
83. Ward J, Bala S, Petrasek J, Szabo G. Plasma microRNA profiles distinguish lethal injury in acetaminophen toxicity: a research study. World J Gastroenterol 2012;18:2798–2804. doi: 10.3748/wjg.v18.i22.2798.
84. Shi Q, Yang X, Mendrick DL. Hopes and challenges in using miRNAs as translational biomarkers for drug-induced liver injury. Biomark Med 2013; 7:307–315. doi: 10.2217/bmm.13.9.
85. Yamaura Y, Nakajima M, Takagi S, Fukami T, Tsuneyama K, Yokoi T. Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. Plos One 2012;7:e30250. doi: 10.1371/journal.pone.0030250.
86. Su YW, Chen X, Jiang ZZ, Wang T, Wang C, Zhang Y, et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound-and herbinduced liver injury in rats. Plos One 2012;7:e37395. doi: 10.1371/journal.pone.0037395.
87. Starckx S, Batheja A, Verheyen GR, Jonghe SD, Steemans K, Dijck BV, et al. Evaluation of miR-122 and other biomarkers in distinct acute liver injury in rats. Toxicol Pathol 2013;41:795–804. doi: 10.1177/0192623312464436.
88. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733–1741. doi: 10.1373/clinchem.2010.147405.
89. Lorenzen JM, Thum T. Circulating and urinary microRNAs in kidney disease. Clin J Am Soc Nephrol 2012;7:1528–1533. doi: 10.2215/CJN.01170212.
90. Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, Song PH, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol 2012;41:1871–1878. doi: 10.3892/ijo.2012.1622.
91. Yang X, Greenhaw J, Shi Q, Su Z, Qian F, Davis K, et al. Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity. Toxicol Sci 2012;125:335–344. doi: 10.1093/toxsci/kfr321.
92. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011;54:1767–1776. doi: 10.1002/hep.24538.
93. Jetten MJ, Gaj S, Ruiz-Aracama A, de Kok TM, van Delft JH, Lommen A, et al. ’Omics analysis of low dose acetaminophen intake demonstrates novel response pathways in humans. Toxicol Appl Pharmacol 2012;259:320– 328. doi: 10.1016/j.taap.2012.01.009.
94. Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminopheninduced acute liver injury at first presentation to hospital. Hepatology 2013;58:777–787. doi: 10.1002/hep.26294.
95. Thulin P, Nordahl G, Gry M, Yimer G, Aklillu E, Makonnen E, et al. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int 2014;34:367–378. doi: 10.1111/liv.12322
96. Ding XF, Ding JV, Ning J, Yi F, Chen JK, Zhao DY, et al. Circulating microRNA122 as a potential biomarker for liver injury. Mol Med Rep 2012;5:1428– 1432. doi: 10.3892/mmr.2012.838.
97. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87–98. doi: 10.1016/j.cmet.2006.01.005.
98. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005;438:685– 689. doi: 10.1038/nature04303.
99. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005;309:1577–1581. doi: 10.1126/science.1113329.
100. Lardizabal MN, Nocito AL, Daniele SM, Ornella LA, Palatnik JF, Veggi LM. Reference genes for real-time PCR quantification of microRNAs and messenger RNAs in rat models of hepatotoxicity. Plos One 2012;7: e36323. doi: 10.1371/journal.pone.0036323.
101. Wang Y, Tang N, Hui T, Wang S, Zeng X, Li H, et al. Identification of endogenous reference genes for RT-qPCR analysis of plasma microRNAs levels in rats with acetaminophen-induced hepatotoxicity. J Appl Toxicol 2013;33:1330–1336. doi: 10.1002/jat.2864.